Study of Ravulizumab in Pediatric Participants With Primary IgAN — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Ravulizumab in Pediatric Participants With Primary IgAN — Stella

Recruiting

Back to IgAN trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(14 sites)

United States

Research Site, Palo Alto, California

Research Site, Aurora, Colorado

China

Research Site, Beijing

Research Site, Shanghai

Italy

Research Site, Genova

Key details

Phase

Large-scale testing

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment target

~24 participants

Started

June 2025

Primary completion

July 2028

Age range

2 Years – 18 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov